Peptides

Choosing a Peptide for the Task

Start from the job, not from the vial size. If the task is appetite and body weight, the incretin family is the coherent choice, and the difference between its members is mainly how many gut-hormone receptors each one touches: semaglutide signals through the GLP-1 receptor, tirzepatide adds GIP, and retatrutide and survodutide add the glucagon receptor as well. Cagrilintide comes from a different hormone family, the amylin side, which is why it is discussed next to the incretins rather than counted as one of them. That same row is the one most readers arrive looking for as fat loss.

If the task is cellular or metabolic support rather than appetite, the longevity row is the place to look: NAD+ is a coenzyme rather than a peptide, glutathione is an antioxidant tripeptide, and SS-31, MOTS-c and the short bioregulators act on mitochondria or on regulatory pathways. For mood, focus and sleep the cognitive row is small and specific. If the task is tissue repair or growth hormone output, the two goal pages hold the detail, so read the recovery and growth rows here as a signpost rather than a full protocol. Where the surrounding plan is a cutting phase or a mass-building phase, these vials are read as support rather than as the base.

One filter is worth applying before any of that: check whether the material is a peptide or a small molecule. AOD 9604, AICAR and 5-Amino-1MQ sit in the metabolic row, but they are a growth hormone fragment, an AMPK activator and an NNMT inhibitor respectively, and their handling is not the same as that of a lyophilized peptide. The class boundary holds at the other end too: material sold for the androgen-receptor route is filed under SARMs rather than here. The same boundary runs the other way for oral tablets, which are filed by active substance rather than by peptide class.

Protocol and Duration

Weekly Incretin Schedule

The incretin group is built around one subcutaneous injection a week, and the interval comes from pharmacokinetics rather than convenience: semaglutide stays in circulation for about a week, tirzepatide for about five to six days, cagrilintide for roughly seven days, survodutide for about six days, and mazdutide for around eight days at its higher studied dose. Retatrutide is the exception in documentation terms, because a human half-life has not been published for it; the weekly interval used in studies is a practice convention, not a confirmed figure.

Titration and Short-Acting Material

Weekly products are not started at the top of their range. The published stairs hold each step for at least four weeks before the next increase, and the reason is tolerability: nausea, vomiting and diarrhea cluster on the titration steps and ease when the climb is slow. Short-acting material is dosed on a different clock. MOTS-c is given subcutaneously, usually in the first half of the day, and AICAR is run in courses of roughly four to eight weeks; the short regulatory peptides such as Livagen, Ovagen and Testagen are used in short courses of about one to three weeks.

Course Length

Incretin research protocols run long. Weight-effect studies follow participants for many months, with phase 3 work around retatrutide extending past eighty weeks, and the effect builds gradually rather than showing up in the first days. Nothing in this class needs the hormonal recovery plan that follows a suppressive steroid cycle, because these are not androgens and the studies do not report shutdown of the testosterone axis; what a long course does need is a written schedule and consistent injection timing. Because nothing here suppresses the axis, a plan ends without the restart that post-cycle therapy provides after a suppressive run.

Reconstitution and Storage

Almost everything here arrives as a lyophilized powder and has to be dissolved before use, and the diluent of choice is bacteriostatic water rather than plain sterile water, because the benzyl alcohol in it holds microbial growth down across repeat withdrawals from a multi-dose vial. The arithmetic is simple and worth doing on paper first: a five milligram vial with two milliliters of water gives 2.5 mg per ml, a ten milligram vial with the same two milliliters gives 5 mg per ml, and on a U-100 insulin syringe 0.1 ml reads as 10 units.

Storage follows the same rule across the class. The powder keeps cold, at 2 to 8 degrees Celsius, and goes into the freezer for long-term storage with protection from light. Once reconstituted, the solution stays in the refrigerator at 2 to 8 degrees Celsius and is used within about 28 to 30 days, and it is not frozen, because freeze-thaw cycles cost short peptides their activity. The diluent keeps its own clock: an unopened bacteriostatic water vial holds for two to three years at room temperature, and after the first puncture the working limit is the 28 day default that CDC and USP practice sets for multi-dose vials.

Monitoring and Cautions

What to watch depends on the group. On the incretin side the early signals are gastrointestinal and the pattern is predictable: they appear as the dose climbs and settle when the climb pauses. Because these products act on glucose handling and are studied alongside glucose-lowering medication, adding one of them to an existing protocol is a combination to plan carefully rather than improvise. Some research peptides are also named on anti-doping lists: MOTS-c is prohibited at all times in sport and AICAR has been on the prohibited list since 2009, while the GLP-1 group sits on the monitoring programme rather than the banned list.

Two practical points cover the rest. First, keep a record: what was injected, how much water went into the vial, and where the injection was placed, because without that log a reaction cannot be traced to anything. Second, treat the material for what it is. These are research products rather than licensed medicines, and no figure printed in a vendor chart replaces your own arithmetic on the vial you actually hold. Where a certificate of analysis is published for a batch, that document is the one to read beside the label.

Common Mistakes

The first is reconstituting by eye. The volume of water added fixes every dose on the schedule, so a vial mixed roughly turns a careful plan into guesswork, and a vial left warm or put through a freeze-thaw cycle is simply wasted material. Mix it cold, gently, and write the volume down.

The second is judging the class by one group. The incretins work on appetite over many weeks, the mitochondrial peptides are studied for cellular metabolism, and the repair and growth peptides are a different job again; expecting a metabolic vial to behave like a repair peptide is how a course gets abandoned halfway. The third is ignoring the clock on the diluent and on the reconstituted solution, which is the most common way a good vial is spoiled. The fourth is starting three new things at once, after which nothing can be attributed to anything. Change one variable, keep the record, and let the schedule do its work.